


Listing of the Claims.

The present Listing of the Claims replaces all claims previously presented in the applicatio.

Claim 1 (Currently Amended). A substituted 4-, 5-, 6-, or 7-indole or indoline derivative of Formula


~~wherein W is C, CH or COH and the dotted lines indicate optional bonds and~~

~~wherein A is a group having the formula~~



wherein W is C, CH or COH and the dotted lines indicate optional bonds and

wherein A is a group having the formula:



(IIA)


wherein X is CR^{1A}, CHR^{1A}, N, NR^{1B}, O, or S, where R^{1A} is as defined for R³ to R⁹ below, and where R^{1B} is as defined for R¹⁰ below;

Y is CR^{2A}, CHR^{2A}, N, NR^{2B}, O, or S, where R^{2A} is as defined for R³ to R⁹ below and where R^{2B} is as defined for R¹⁰ below, and

the dotted lines indicate optional bonds;

provided that X and Y are not both [[0]] Q or S;

A is a group having the formula




wherein X is CR^{1A}, CHR^{1A}, N, NR^{1B}, O, or S, where R^{1A} is as defined for R³ to R⁹ below, and where R^{1B} is as defined for R¹⁰ below;

U is C, CH, or N; and

the dotted lines indicate optional bonds; or

A is a group having the formula



wherein U is C, CH, or N;

Y is CR^{2A} , CHR^{2A} , N, NR^{2B} , O, or S, where R^{2A} is as defined for R^3 to R^9 below and where R^{2B} is as defined for R^{10} below; and

the dotted lines indicate optional bonds;

n is 0, 1, 2, 3, 4, or 5, and m is 0, 1, 2, 3, 4, or 5;

Z is CH_2 , O, S, CO, SO, or SO_2 , provided that if n is 0 then Z is CH_2 ;

R^3 - R^9 and R^{11} to R^{12} are independently selected from hydrogen, halogen, cyano, nitro, C_{1-6} -alk(en/yn)yl, C_{1-6} -alkenyl, C_{1-6} alkynyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, hydroxy, hydroxy- C_{1-6} -alkyl, C_{1-6} alkoxycarbonyl, C_{3-8} -cycloalk(en)yl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, C_{3-8} -cycloalk(en)yl- C_{1-6} alk(en/yn)yl, C_{3-8} -cycloalkyl- C_{1-6} -alkyl, C_{3-8} -cycloalkyl- C_{1-6} -alkenyl, C_{3-8} -cycloalkyl- C_{1-6} alkynyl, C_{3-8} cycloalkenyl- C_{1-6} -alkyl, C_{3-8} -cycloalkenyl- C_{1-6} alkenyl, C_{3-8} -cycloalkenyl- C_{1-6} -alkynyl, C_{1-6} alkylcarbonyl, phenylcarbonyl, halogen substituted phenylcarbonyl, trifluoromethyl, trifluoromethylsulfonyloxy, C_{1-6} alkylsulfonyl, aryl and

heteroaryl, or two adjacent groups taken from R³ - R⁹ may together form a methylenedioxy group,

or two adjacent groups R⁷ - R⁹ may together form a cyclopentyl or cyclohexyl ring which may be substituted with one or more methyl groups,

or one of R³-R⁹ may alternatively be a group -NR¹³R¹⁴ wherein R¹³ is as defined for R¹⁰ below

and R¹⁴ is hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, C₁₋₆-alkenyl, C₁₋₆-alkynyl, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkenyl, C₃₋₈-cycloalkyl-C₁₋₆-alkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkenyl, C₃₋₈-cycloalkyl-C₁₋₆-alkynyl, C₃₋₈-cycloalkenyl-C₁₋₆-alkyl, C₃₋₈-cycloalkenyl-C₁₋₆-alkenyl, C₃₋₈-cycloalkenyl-C₁₋₆-alkynyl, aryl, heteroaryl, aryl-C₁₋₆-alkyl, or heteroaryl-C₁₋₆-alkyl;


R¹⁰ is

- hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, C₁₋₆-alkenyl, C₁₋₆-alkynyl, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkenyl, C₃₋₈-cycloalkyl-C₁₋₆-alkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkenyl, C₃₋₈-cycloalkyl-C₁₋₆-alkynyl, C₃₋₈-cycloalkenyl-C₁₋₆-alkyl, C₃₋₈-cycloalkenyl-C₁₋₆-alkenyl, C₃₋₈-cycloalkenyl-C₁₋₆-alkynyl, aryl, heteroaryl, aryl-C₁₋₆-alkyl, heteroaryl-C₁₋₆-alkyl, acyl, thioacyl, C₁₋₆-alkylsulfonyl, trifluoromethylsulfonyl; arylsulfonyl, or heteroarylsulfonyl;
- R¹⁵VCO- wherein V is O or S and R¹⁵ is C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, C₁₋₆-alkenyl, C₁₋₆-alkynyl, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkenyl, C₃₋₈-cycloalkyl-C₁₋₆-alkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkenyl, C₃₋₈-cycloalkyl-C₁₋₆-alkynyl, C₃₋₈-cycloalkenyl-C₁₋₆-alkyl, C₃₋₈-cycloalkenyl-C₁₋₆-alkenyl, C₃₋₈-cycloalkenyl-C₁₋₆-alkynyl, aryl, or heteroaryl; or

- a group $R^{16}R^{17}NCO-$ or $R^{16}R^{17}NCS-$ wherein R^{16} and R^{17} are independently selected from hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, C_{1-6} -alkenyl, C_{1-6} -alkynyl, C_{1-6} -alkyl, C_{3-8} -cycloalkyl, C_{3-8} -cycloalkenyl, C_{3-8} -cycloalkyl- C_{1-6} -alkyl, C_{3-8} -cycloalkyl- C_{1-6} -alkenyl, C_{3-8} -cycloalkyl- C_{1-6} -alkynyl, C_{3-8} -cycloalkenyl- C_{1-6} -alkyl, C_{3-8} -cycloalkenyl- C_{1-6} -alkenyl, C_{3-8} -cycloalkenyl- C_{1-6} -alkynyl, heteroaryl, or aryl, or R^{16} and R^{17} together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, morpholinyl, or perhydroazepin group;

or an acid addition salt thereof.


Claim 2 (original). A compound according to claim 1 wherein A is a group having the formula



(IIA)


wherein X, Y, the dotted lines and R^3 - R^6 are as defined in claim 1.

Claim 3 (original). A compound according to claim 2 wherein A is a group having the formula




wherein R^3 to R^6 and the dotted lines are as defined in claim 2.

Claim 4 (original). A compound according to claim 3 wherein A is a group having the formula



wherein R^3 to R^6 and the dotted lines are as defined in claim 3.

Claim 5 (original). A compound according to claim 1 having the formula




wherein R^7 to R^{12} , W, A, Z, n, m and the dotted lines are as defined in claim 1.


Claim 6 (Previously presented). A compound according to claim 1 wherein Z is CH_2 and $n + m$ is 0, 1, 2, 3, 4, 5, or 6.

Claim 7 (canceled).

Claim 8 (original). A compound according to claim 1 having the formula




wherein R^7 to R^{12} , W , Z , n , m and the dotted lines are as defined in claim 1 and A is a group having the formula




wherein X , Y , the dotted lines and R^3 - R^6 is as defined in claim 1.

Claim 9 (original). A compound according to claim 8 wherein A is a group having the formula



wherein R^3 to R^6 and the dotted line is as defined in claim 8.

Claim 10 (original). A compound according to claim 9 wherein A is a group having the formula



wherein R^3 to R^6 and the dotted lines is as defined in claim 9.

Claim 11 (Previously presented). A compound of claim 1 wherein Z is CH_2 and $n + m$ is 0, 1, 2, 3, 4, 5, or 6 and R^3 - R^9 and R^{11} - R^{12} is hydrogen, halogen, cyano, nitro, C_{1-6} -alkyl, C_{1-6} -alkoxy, hydroxy, hydroxy- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyl and trifluoromethyl; and R^{10} is hydrogen.

Claim 12 (canceled).

Claim 13 (Previously presented). A compound according to claim 1 which is
 1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)-1,2,3,6-tetrahydropyridine,
 1-(2-(5-Fluoro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)-1,2,3,6-tetrahydropyridine,
 1-(3-(5-Fluoro-3-benzofuranyl)-1-propyl)-4-(1H-indol-4-yl)-1,2,3,6-tetrahydropyridine,
 1-(2-(6-Chloro-1H-indol-3-yl)-4-(1H-indol-4-yl)piperidine,

1-(2-(4-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperidine,
4-(1H-Indol-4-yl)-1-(2-(5-methyl-1H-indol-3-yl)ethyl)piperidine,
4-(1H-Indol-4-yl)-1-(2-(1H-indol-3-yl)ethyl)piperidine,
4-(1H-Indol-4-yl)-1-(3-(4-methyl-3-benzofuranyl)-1-propyl)piperidine,
or a pharmaceutically acceptable acid addition salt thereof.

Claim 14 (Previously presented). A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof and at least one pharmaceutically acceptable carrier or diluent.

Claims 15-16 (Canceled).

Claim 17 (Previously presented). A method for the treatment of a disorder or disease of a living animal body, which is responsive to the inhibition of serotonin reuptake and antagonism of 5-HT_{1A} receptors comprising administering to such a living animal body, a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.

Claim 18 (Previously presented). A method for the treatment of an affective disorder in a living animal body, comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.

Claim 19 (Previously presented). The method of claim 17 wherein said living animal body is a human.

Claim 20 (Previously presented). The method of claim 18 wherein said living animal body is a human.

Claim 21 (Previously presented). The method of claim 20 wherein said affective disorder is selected from the group consisting of depression, psychosis and anxiety disorder.

Claim 22 (Previously presented). The method of claim 20 wherein said affective disorder is an anxiety disorder selected from the group consisting of general anxiety disorder, panic disorder and obsessive compulsive disorder.